Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites

被引：28

作者：

Deng, Lihui ^{[1
,2
]}

Tang, Hong ^{[1
,2
]}

机构：

[1] Sichuan Univ, W China Hosp, Ctr Infect Dis, Chengdu 610041, Sichuan Provinc, Peoples R China

[2] Sichuan Univ, State Key Lab Biotherapy, Div Infect Dis, Chengdu 610041, Sichuan Provinc, Peoples R China

来源：

HEPATOLOGY RESEARCH | 2011年 / 41卷 / 11期

关键词：

chronic hepatitis B; drug resistance; hepatitis B virus; nucleos(t)ide analogs;

D O I：

10.1111/j.1872-034X.2011.00873.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

Nucleos(t)ide analogs (NAs) have become the mainstream drugs for the treatment of chronic hepatitis B virus infection. Drug resistance to NAs, however, has posed a major obstacle in obtaining sustained viral suppression. Standardized definitions of terms and nomenclature in discussing NAs resistance have been proposed. Drug resistance to NAs is produced by a combination of viral, host and antiviral drug factors. A detailed understanding of the mechanisms and effects of mutation sites that cause resistance to NAs is important for the design of rational treatment and management of patients with existing drug resistance.

引用

页码：1017 / 1024

页数：8

共 67 条

[1]

Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., Lok A.S., Management of hepatitis B: summary of a clinical research workshop, Hepatology, 45, pp. 1056-1075, (2007)

[2]

Lok A.S., Zoulim F., Locarnini S., Et al., Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management, Hepatology, 46, pp. 254-265, (2007)

[3]

Holoman J., Glasa J., EASL clinical practice guidelines, J Hepatol, 51, pp. 821-822, (2009)

[4]

Lok A.S., McMahon B.J., Chronic hepatitis B: update 2009, Hepatology, 50, pp. 661-662, (2009)

[5]

Stuyver L.J., Locarnini S.A., Lok A., Et al., Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region, Hepatology, 33, pp. 751-757, (2001)

[6]

Zoulim F., Locarnini S., Hepatitis B virus resistance to nucleos(t)ide analogues, Gastroenterology, 137, pp. 1593-1608, (2009)

[7]

Tillmann H.L., Antiviral therapy and resistance with hepatitis B virus infection, World J Gastroenterol, 13, 1, pp. 125-140, (2007)

[8]

Locarnini S., Bowden S., Drug resistance in antiviral therapy, Clin Liver Dis, 14, 3, pp. 439-459, (2010)

[9]

Zhou T., Saputelli J., Aldrich C.E., Deslauriers M., Condreay L.D., Mason W.S., Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine, Antimicrob Agents Chemother, 43, pp. 1947-1954, (1999)

[10]

Werle-Lapostolle B., Bowden S., Locarnini S., Et al., Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy, Gastroenterology, 126, pp. 1750-1758, (2004)

← 1 2 3 4 5 6 7 →